On Sep 28, major Wall Street analysts update their ratings for $Travere Therapeutic (TVTX.US)$, with price targets ranging from $17 to $23.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $18.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $23 to $19.
Guggenheim analyst Vamil Divan maintains with a buy rating, and adjusts the target price from $25 to $23.
Wedbush analyst Laura Chico maintains with a buy rating, and adjusts the target price from $16 to $17.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and adjusts the target price from $23 to $18.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Travere Therapeutics has announced a halt in enrollment for the pegtibatinase phase 3 HARMONY study due to manufacturing challenges, which is acknowledged as a delay in the commercial portfolio. The company anticipates that the trial could restart by 2026 at the earliest. Despite the setback, the program was previously not considered highly valuable by many, and the management has highlighted that the disruptions should not affect the trial design and enrollment. Consequently, it is anticipated that the influence on near-term sentiment will be relatively limited.
Travere Therapeutics has voluntarily paused enrollment in their Phase 3 HARMONY study of pegtibatinase due to challenges encountered with manufacturing scale-up. Analysts have expressed that while the pause is unfortunate, it is noteworthy as pegtibatinase was seen as an opportunity to diversify beyond Filspari. The anticipated launch has now been adjusted to fiscal 2030, based on projections that enrollment will recommence in 2026.
Following Travere Therapeutics' announcement of a voluntary pause on the Phase 3 HARMONY study for pegtibatinase in treating classical homocystinuria, or HCU, the timeline for larger patient enrollment and eventual commercialization is now anticipated to be significantly delayed, with expectations to resume study enrollment in 2026. Consequently, the probability of success for pegtibatinase has been moderately reduced, and the forecast for sales has been deferred by two years.
Here are the latest investment ratings and price targets for $Travere Therapeutic (TVTX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.